“Regardless of tumor localization or size, growth occurs only within the first 5 years after diagnosis”This interesting quote is from “The Natural History of Vestibular Schwannoma” by Sven-Eric Stangerup et al from 2006.
http://acusticusneurinom.dk/wp-content/uploads/2015/10/natural-history-of-vs.pdfInteresting snippets are:
* 552 prospectively registered patients were followed (1975 to 2004)
* 28.9% of extrameatal tumors grew
* an increase of more than 2 mm in the largest extrameatal diameter was defined as growth
* a decrease of more than 2 mm in the largest extrameatal diameter was defined as shrinkage
* Of the 322 extrameatal tumors, over the entire observation period:
- 0.9% decreased in size (n = 3)
- 70.2% was unchanged in size (n = 226)
- 28.9% increased in size (n = 93)
- 58 (62% of 93) during first year
- 24 patients (26% of 93) during the second year
- 9 patients (10% of 93) during the third year
- 2 patients (2% of 93) during the fourth year
- No tumor growth occurred after the fourth year of observation
* There was no significant difference in number of patients with growth between male and female
patients, different age groups, or small (<10 mm) and larger (>10 mm) extrameatal tumors
* Of the 93 patients (intrameatal) with tumor growth:
- 58 patients were operated on
- 5 patients were irradiated
- 10 patients died as a result of unrelated reasons
- 20 patients were either waiting for operation or radiotherapy, or continued observation due to specific patient choice, old age, or significance concurrent disease
* The data are additionally strengthened by the prospective and consecutive one-center registration of all patients diagnosed during the period from 1976 to 2004 in Denmark, with a population of 5.2 million inhabitants. The data are thus without patient referral bias.
* All previous studies on VS growth have been subject to considerable referral bias and additional patient selection bias
All of this is interesting. I wondered if the findings reported here have changed over the years, so I searched for contemporary articles by the same lead author. The most recent, regarding this topic is “Active Treatment is Not Indicated in the Majority of Patients Diagnosed with a Vestibular Schwannoma: A review on the Natural History of Hearing and Tumor Growth” 2014
http://www.bhtinformatie.nl/pdf/ingrijpen.pdf .
Interesting snippets are:
* In order to justify invasive treatment either by surgery or radiotherapy for these smaller tumors the outcome should be superior to that resulting from the natural history of the disease
* the occurrence of significant growth in 20-45% after 3-5 years of observation.
* Tumor regression or shrinkage is reported in 4-22%
* tumor growth occurring beyond the fifth year of observation is very rare, but is, however, still observed
* a larger percentage [of extrameatal tumors] exhibited growth, ranging between 29 and 54%
* hearing will deteriorate faster in patients with growing, as opposed to stable or regressing tumors
* On average, 60% of patients presenting with good hearing at diagnosis will maintain a good hearing level after 5 years of observation
* patients with a normal SD [speech discrimination] at diagnosis will maintain a good hearing level which is markedly better than patients with only a small discrimination loss, and it is especially noteworthy that 75% maintain good hearing after 10 years.
* the main arguments in favor of primary active treatment (surgery or radiotherapy) is to preserve hearing function.
* Hearing preservation by both surgery and radiotherapy show that on average, around 50% of patients preserve good or serviceable hearing short-term by both modalities
Of the few papers that observed tumor growth after 5 years, “Conservative Management of Vestibular Schwannoma: Expectations Based on the Length of the Observation Period”
https://www.ncbi.nlm.nih.gov/pubmed/24914786 [abstract only]
Interesting snippets are:
* 37.7% of tumors (n = 43) showed growth of at least 2 mm.
* Among the patients in the current study, an MRI negative for growth at 2 years of observation yielded only a 12% chance of future growth.
* Of those with a negative MRI at 5 years, only 4% grew by later follow-up
* Not all tumors that grew necessitated further treatment.
* We found that 85.7% of patients who started with an initial AAO-HNS hearing Class A were able to retain a Class A or B (serviceable hearing) at an average follow-up time of 4.8 years.
Summary: Tumor growth occurring beyond the fifth year of observation is very rare.